Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine…
DUBLIN, 16-Jan-2018 — /EuropaWire/ — At Shire, we’ve been committed to the hemophilia community and the lives of every patient afflicted…